When the System Doesn’t Fit the Patient: New Evidence on the Hidden Gaps in Women’s Healthcare
The Quiet Mismatch Between What Medicine Knows — and What It Applies
There’s a strange paradox unfolding in healthcare.
On one hand, medicine has never been more advanced: AI-driven diagnostics, precision oncology, gene mapping, real-time monitoring, and treatments tailored to tumor profiles rather than tumor locations.
On the other hand, most women still receive care based on models, guidelines, and assumptions that were developed without them, or worse, in ways that treat their biology as a deviation rather than a design.
That sounds abstract, until you see how it plays out in practice.
Our survey in collaboration with the HBA and HBA Think Tank of 200 physicians across five specialties and six countries makes something unmistakable: the problem isn’t lack of awareness, it’s the system itself. Clinicians recognize sex-based differences every day. What they don’t have are the tools, pathways, and structures to act on them.
What the Data Shows
Across the survey:
53% of physicians said the lack of sex-specific research and treatment guidelines limits their ability to deliver proper care
47% acknowledged systemic bias affects the way women are treated in clinical settings
80% report routinely witnessing sex-based differences in disease progression or response to treatment
Yet fewer than 30% feel equipped with the resources or tools to address those differences
Where the System Breaks Down
These gaps aren’t generic. They follow clear patterns — and some of them are startling.
Oncology
In clinical practice, women experience 34% more severe side effects from cancer treatment, and nearly 50% more in immunotherapy.
Yet in clinical research:
only 0.5% of oncology trials include curated post-treatment sex comparisons.And in routine care:
90% of men undergoing radiation are asked about sexual side effects.
Only 10% of women are.
This means women are more likely to be harmed, and less likely to have the harm acknowledged.
Cardiology
Cardiology may be the clearest example of system misalignment.
Stroke risk triples in the first two weeks postpartum, yet this window rarely exists in monitoring protocols.
77% of cardiologists report difficulty adapting standard protocols to women.
Hypertension research was named a priority by 78% of surveyed physicians, especially around hormonal transitions.
And across countries — U.S., Germany, Brazil, Thailand, Egypt, Morocco — stroke was the #1 requested area for sex-specific research.
Endocrinology
The data makes one statistic unavoidable:
PCOS affects 10% of women — but 70% remain undiagnosed.
That alone is a system failure.
Meanwhile:
100% of German clinicians emphasized the need for earlier detection and preventive care
80% of Brazilian clinicians identified osteoporosis as a top priority
Physicians consistently named pregnancy, lactation, and menopause as moments where endocrine care is least aligned with reality
.
Neurology
Women aren’t an edge case here, they’re the dominant pattern.
Migraine: three times more common in women
MS relapse peaks 3–6 months postpartum
Women represent ~⅔ of Alzheimer’s cases and decline faster after diagnosis
Despite this, treatment pathways rarely reflect menstrual cycles, pregnancy, postpartum physiology, or menopause, even though neurologists in the survey overwhelmingly agreed these stages change disease course.
Ophthalmology
Ophthalmology is often treated as neutral territory, yet it isn’t.
75% of ophthalmologists say hormonal shifts meaningfully affect retinal health
Age-related macular degeneration, the leading cause of irreversible blindness, disproportionately affects women and was named the top research priority by 89% of respondents
Conditions like uveitis and diabetic retinopathy were flagged as urgently needing sex-specific insight
This specialty reveals how assumptions about neutrality can obscure meaningful biological differences.
A Pattern Across Countries
The exact barrier changes based on income level:
In high-income countries, the missing pieces are tools, guidelines, and practical integration into clinical workflow.
In middle-income settings, the gap centers on diagnostics, access pathways, and awareness.
And in low-income settings, the foundational challenge is infrastructure, along with the absence of sex-specific research that can be translated into practice.
The recognition, however, that sex matters in treatment pathways was universal.
What This Means
The issue is not only that we don’t know enough.
It’s that the system can’t operationalize what the science already shows.
Until reference ranges, reimbursement models, clinical trials, decision-support tools, and training reflect biological reality, the gap won’t close.













Loved reading this!
This is so will written! Thank you.